Bristol Aims To Be First To Market With Novel Diabetes Drug Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.
You may also be interested in...
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.
AstraZeneca Executive VP, Discovery Research, Jan Lundberg, An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec addresses oncology pipeline, Bristol diabetes deal.